MannKind Corporation (NASDAQ:MNKD) is a U.S.-based biopharmaceutical company focused on developing and commercializing ...

MannKind (MNKD) reported top-level 30-week results from Phase 4 INHALE-3 study, in which additional patients living with type 1 ...

On Friday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.6 which represents a decrease of $-0.10 or -1.49% from the prior close of $6.7. The stock opened at $6.7 and touched a low of ...

MannKind Corp (MNKD) stock saw a modest uptick, ending the day at $6.66 which represents a slight increase of $0.10 or 1.52% from the prior close of $6.56. The stock opened at $6.61 and touched a low ...

Discover MannKind Corp's innovative patent for synthesizing N-protected 3,6-aminoalkyl-2,5-diketopiperazines, enhancing organic chemistry and pharmaceutical advancements.

Check the time stamp on this data. Updated AI-Generated Signals for Mannkind Corporation (MNKD) available here: MNKD.

Air bubble formation from pressure changes causes the pump to deliver about 0.6 extra units on ascent and about 0.5 less on ...

Port City Daily publishes the Food Truck Tracker every Friday, so folks can know where to access the best mobile eats while ...

Sept. 18, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients ...

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...